TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39543593

Group type: COMPARATOR
Intervention: Conventional impression (C1) using an individual tray with zinc oxide eugenol
Number of subjects: 15

Group type: COMPARATOR
Intervention: One-step simplified impression (C2) using a stock tray with irreversible hydrocolloid
Number of subjects: 15

Group type: COMPARATOR
Intervention: Digital impression without AI scanning (D1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Digital impression with AI scanning (D2)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Modified digital impression (D3)
Number of subjects: 15
Study: 39543697

Group type: EXPERIMENTAL
Intervention: Locavore-I-SF score
Number of subjects: 834
Study: 39543718

Group type: EXPERIMENTAL
Intervention: Community navigation intervention
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Recruitment
Number of subjects: 80
Study: 39543756

Group type: EXPERIMENTAL
Intervention: ICU patients surviving the first year after admission
Number of subjects: 140008

Group type: EXPERIMENTAL
Intervention: ICU patients excluding cardio-thoracic admissions
Number of subjects: 140008

Group type: EXPERIMENTAL
Intervention: Subgroup of ICU patients ≥75 years old surviving the first year
Number of subjects: 140008

Group type: EXPERIMENTAL
Intervention: ICU patients with acute-on-chronic respiratory failure
Number of subjects: 140008

Group type: EXPERIMENTAL
Intervention: ICU patients with other respiratory causes
Number of subjects: 140008

Group type: EXPERIMENTAL
Intervention: ICU patients admitted for septic shock
Number of subjects: 140008
Study: 39543797

Group type: EXPERIMENTAL
Intervention: Neofunctional deep breathing (NDB) technique
Number of subjects: 44

Group type: COMPARATOR
Intervention: Attention control intervention
Number of subjects: 44
Study: 39544014

Group type: EXPERIMENTAL
Intervention: Ergothioneine (25 mg per capsule, taken 3 times a week for one year)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (taken 3 times a week for one year)
Number of subjects: 19
Study: 39544430

Group type: EXPERIMENTAL
Intervention: NabPaclitaxel-PIPAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic NabPaclitaxel-Gemcitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatment of NabPaclitaxel-PIPAC and systemic NabPaclitaxel-Gemcitabine
Number of subjects: 0
Study: 39544897

Group type: EXPERIMENTAL
Intervention: Investigational products (amlitelimab and nerandomilast)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39544899

Group type: EXPERIMENTAL
Intervention: Avenciguat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39544960

Group type: EXPERIMENTAL
Intervention: iStent with phacoemulsification (phaco-iStent)
Number of subjects: 71

Group type: COMPARATOR
Intervention: phacoemulsification alone (control group)
Number of subjects: 71
Study: 39545359

Group type: EXPERIMENTAL
Intervention: FirmTech device
Number of subjects: 50

Group type: COMPARATOR
Intervention: Eddie by Giddy device
Number of subjects: 50
Study: 39545423

Group type: EXPERIMENTAL
Intervention: Awareness of disease incurability
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Being aware of disease incurability
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Uncertainty about disease incurability
Number of subjects: 251
Study: 39545451

Group type: EXPERIMENTAL
Intervention: Reference adalimumab (cH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Switching between reference adalimumab and GP2017 (H2H)
Number of subjects: 0
Study: 39545461

Group type: EXPERIMENTAL
Intervention: QHRD106 (18,900 IU single dose)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: QHRD106 (8,400 IU multiple doses)
Number of subjects: 94

Group type: COMPARATOR
Intervention: UKN (0.15 PNA units intravenously for 7 days)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 39545610

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus PD-1 inhibitor and radiotherapy
Number of subjects: 433

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 433
Study: 39545836

Group type: EXPERIMENTAL
Intervention: Human Caring Theory-based breastfeeding education and support program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard breastfeeding training in a childbirth education class (control)
Number of subjects: 100
Study: 39545967

Group type: EXPERIMENTAL
Intervention: Once-daily iTBS
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Twice-daily iTBS
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control (sham)
Number of subjects: 158
Study: 39546030

Group type: EXPERIMENTAL
Intervention: 80CS_20G (coarse semolina with 20% gluten)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 80FS_20G (fine semolina with 20% gluten)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 95FS_5G (fine semolina with 5% gluten)
Number of subjects: 16
Study: 39546040

Group type: EXPERIMENTAL
Intervention: Almond consumption (50 g daily)
Number of subjects: 34
Study: 39546129

Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: 0.75% ruxolitinib cream
Number of subjects: 1208

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 1208
Study: 39546311

Group type: EXPERIMENTAL
Intervention: OBLS education (blended learning curriculum with simulation-based training)
Number of subjects: 46
Study: 39546315

Group type: EXPERIMENTAL
Intervention: Open Sky School Program (nature-based intervention), 2 hours per week for 12 weeks
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Open Sky School Program (nature-based intervention)
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Control group (usual classes)
Number of subjects: 1015
Study: 39546314

Group type: EXPERIMENTAL
Intervention: Intensive Home Treatment (IHT)
Number of subjects: 200
Study: 39546348

Group type: EXPERIMENTAL
Intervention: CI-oSurg (web-based communication intervention)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Qualitative one-to-one semistructured interviews
Number of subjects: 24
Study: 39546477

Group type: EXPERIMENTAL
Intervention: Immediate office-based vergence/accommodative therapy with movement (OBVAM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed OBVAM (by six weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Immediate OBVAM
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed OBVAM
Number of subjects: 100
Study: 39546502

Group type: EXPERIMENTAL
Intervention: glargine U100
Number of subjects: 5047

Group type: EXPERIMENTAL
Intervention: glimepiride
Number of subjects: 5047

Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 5047

Group type: EXPERIMENTAL
Intervention: sitagliptin
Number of subjects: 5047
Study: 39546625

Group type: EXPERIMENTAL
Intervention: Bigfoot Unity Diabetes Management System
Number of subjects: 102
Study: 39546748

Group type: EXPERIMENTAL
Intervention: Venetoclax plus mini-hyper-CVD (cyclophosphamide, vincristine, dexamethasone alternating with methotrexate and cytarabine)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Venetoclax plus mini-hyper-CVD
Number of subjects: 19
Study: 39546931

Group type: EXPERIMENTAL
Intervention: Vigil (gemogenovatucel-T)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 39546957

Group type: EXPERIMENTAL
Intervention: Nomogram developed based on a Cox regression model incorporating 10 variables (age, male sex, smoking status, waist circumference, systolic blood pressure, fasting glucose, lipid abnormalities, antihypertensive, glucose-lowering, and lipid-lowering medications)
Number of subjects: 7933

Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 7933
Study: 39547230

Group type: EXPERIMENTAL
Intervention: High-dose AAV8.TBG.hARSB gene therapy (single intravenous infusion)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Enzyme replacement therapy (ERT)
Number of subjects: 4
Study: 39547252

Group type: EXPERIMENTAL
Intervention: Pembrolizumab with preoperative radiotherapy and surgery
Number of subjects: 143

Group type: COMPARATOR
Intervention: Preoperative radiotherapy and surgery (control group)
Number of subjects: 143
Study: 39547249

Group type: EXPERIMENTAL
Intervention: FYTF-919 (Zhongfeng Xingnao) oral solution, 33 mL every 8 hours for 28 days (or 25 mL via nasogastric tube if swallowing impaired)
Number of subjects: 1648

Group type: COMPARATOR
Intervention: Placebo, matching appearance and administration as FYTF-919
Number of subjects: 1648

Group type: EXPERIMENTAL
Intervention: FYTF-919
Number of subjects: 1648

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1648
Study: 39547694

Group type: EXPERIMENTAL
Intervention: bDMARDs in RCTs
Number of subjects: 5654

Group type: COMPARATOR
Intervention: PsABio
Number of subjects: 5654
Study: 39547832

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) implantation with prolonged dual antiplatelet therapy (DAPT) for 36 months
Number of subjects: 505

Group type: COMPARATOR
Intervention: Bioresorbable vascular scaffold (BVS) implantation with shorter DAPT duration
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) implantation with prolonged DAPT
Number of subjects: 505
Study: 39547931

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 1064

Group type: COMPARATOR
Intervention: c-IVF
Number of subjects: 1064
Study: 39547948

Group type: EXPERIMENTAL
Intervention: Personality feedback report with tailored self-care tips
Number of subjects: 372

Group type: COMPARATOR
Intervention: Generic reading on personality theory
Number of subjects: 372
Study: 39547955

Group type: EXPERIMENTAL
Intervention: Behavioral Activation plus Care as Usual (BA + CAU)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 153
Study: 39547981

Group type: EXPERIMENTAL
Intervention: Lipid-lowering drug targets gene variants (specific SNPs not detailed)
Number of subjects: 0
Study: 39548016

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 9971

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9971
Study: 39548019

Group type: EXPERIMENTAL
Intervention: Equimolar oxygen-nitrous oxide (EMONO)
Number of subjects: 677
Study: 39548032

Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention in the emergency department
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no physiotherapy intervention)
Number of subjects: 104
Study: 39548306

Group type: EXPERIMENTAL
Intervention: G-CSF only (G)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard chemotherapy/G-CSF (CG)
Number of subjects: 0
Study: 39548320

Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39548414

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO), n = 35
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (control), n = 36
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study: 39548423

Group type: EXPERIMENTAL
Intervention: Virtual reality glasses showing cartoons in sign language (Study group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional behavior management approach (Control group)
Number of subjects: 40
Study: 39548456

Group type: EXPERIMENTAL
Intervention: Attractive targeted sugar bait (ATSB) stations (0.11% dinotefuran w/w) maintained on exterior walls for 7 months (December-June) during high malaria transmission season.
Number of subjects: 4494

Group type: COMPARATOR
Intervention: Control arm (no ATSB) in the context of standard of care vector control (insecticide-treated nets and/or indoor residual spraying).
Number of subjects: 4494

Group type: EXPERIMENTAL
Intervention: Attractive targeted sugar bait (ATSB) stations (0.11% dinotefuran w/w).
Number of subjects: 4494

Group type: COMPARATOR
Intervention: Control arm (no ATSB).
Number of subjects: 4494
Study: 39548476

Group type: EXPERIMENTAL
Intervention: Communication during consultation with clinicians (ophthalmologist/oncologist)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Satisfaction with the information received
Number of subjects: 250
Study: 39548560

Group type: EXPERIMENTAL
Intervention: 30 kHz KHFAC stimulation
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 40 kHz KHFAC stimulation
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 50 kHz KHFAC stimulation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 34
Study: 39548582

Group type: EXPERIMENTAL
Intervention: Ginkgo diterpene lactone meglumine (GDLM)
Number of subjects: 3219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3219
Study: 39548608

Group type: EXPERIMENTAL
Intervention: Kabat rehabilitation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Mime therapy
Number of subjects: 72
Study: 39548607

Group type: EXPERIMENTAL
Intervention: Illioinguinal/iliohypogastric nerve block with 20 ml of 0.25% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wound infiltration with 10 ml of 0.25% ropivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 39548963

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS)
Number of subjects: 60
Study: 39549022

Group type: EXPERIMENTAL
Intervention: IN FOCUS (synchronous, virtual mind-body group resiliency intervention)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual Care (UC; synchronous, virtual community group support referral)
Number of subjects: 64
Study: 39549213

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (dietary intervention)
Number of subjects: 55
Study: 39549308

Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Classic rehabilitation strength training (CRST)
Number of subjects: 30
Study: 39549539

Group type: EXPERIMENTAL
Intervention: SLIM-intervention (health technology, motivational interviewing, feedback, and goal setting) implemented in prenatal visits continuing to 12 weeks postpartum.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract).
Number of subjects: 54
Study: 39549554

Group type: EXPERIMENTAL
Intervention: Low dose of spermidine, nicotinamide, PEA, and OEA supplements
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Medium dose of spermidine, nicotinamide, PEA, and OEA supplements
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: High dose of spermidine, nicotinamide, PEA, and OEA supplements
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (wheat flour)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: All supplement doses combined
Number of subjects: 5
Study: 39549678

Group type: EXPERIMENTAL
Intervention: Entrectinib (≥600 mg once daily)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Crizotinib (250 mg twice daily)
Number of subjects: 179
Study: 39549719

Group type: EXPERIMENTAL
Intervention: Setmelanotide (subcutaneous, once daily for 52 weeks, starting at 0.5 mg with increments of 0.5 mg every 2 weeks)
Number of subjects: 12
Study: 39549720

Group type: EXPERIMENTAL
Intervention: HIPEC (cisplatin 75 mg/m²)
Number of subjects: 415

Group type: COMPARATOR
Intervention: No HIPEC
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: HIPEC
Number of subjects: 415
Study: 39549817

Group type: COMPARATOR
Intervention: Biologics (CD: 73.2%, UC: 30.3%)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Immunosuppressants (CD: 65.3%, UC: 58.6%)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Aminosalicylates (CD: 62.4%, UC: 97.9%)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Corticosteroids (CD: 55.4%, UC: 69.7%)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Surgery (CD: 17.8%, UC: 1.4%)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Hospitalizations (CD: 33.7%, UC: 21.4%)
Number of subjects: 246
Study: 39550172

Group type: EXPERIMENTAL
Intervention: Glofit-GemOx
Number of subjects: 274

Group type: COMPARATOR
Intervention: R-GemOx
Number of subjects: 274
Study: 39550530

Group type: EXPERIMENTAL
Intervention: 18-month meditation-based program
Number of subjects: 134

Group type: COMPARATOR
Intervention: Active control group (non-native language training)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Passive control group (no intervention)
Number of subjects: 134
Study: 39550532

Group type: EXPERIMENTAL
Intervention: Healthy Habits in Pregnancy and Beyond (HHIPBe) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ten Top Tips for a Healthy Weight (10TT)
Number of subjects: 0
Study: 39550717

Group type: EXPERIMENTAL
Intervention: Behaviorally informed, electronically delivered, letter-based nudges
Number of subjects: 59458

Group type: EXPERIMENTAL
Intervention: Behaviorally informed, electronically delivered, letter-based nudges (cardiovascular-gain frame letter)
Number of subjects: 59458
Study: 39550716

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 6001

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6001
Study: 39550720

Group type: EXPERIMENTAL
Intervention: CABG plus partial cardiac denervation
Number of subjects: 430

Group type: COMPARATOR
Intervention: CABG only (Control)
Number of subjects: 430
Study: 39550721

Group type: EXPERIMENTAL
Intervention: Finerenone (titrated to 20 mg or 40 mg)
Number of subjects: 6001

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6001

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 6001
Study: 39551007

Group type: EXPERIMENTAL
Intervention: Adjunct dextromethorphan (30 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Adjunct placebo
Number of subjects: 60
Study: 39551040

Group type: EXPERIMENTAL
Intervention: Palbociclib (PAL) with letrozole (1L)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Palbociclib (PAL) in 1L
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Palbociclib (PAL)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Palbociclib (PAL) with fulvestrant (first and later line)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Palbociclib (PAL) with anastrozole or exemestane (1L) and letrozole (later line)
Number of subjects: 388
Study: 39551057

Group type: EXPERIMENTAL
Intervention: Community-based screening and treatment for Chlamydia trachomatis and Neisseria gonorrhoeae (males and females) and Trichomonas vaginalis (females only) offered over 12 months.
Number of subjects: 6361

Group type: COMPARATOR
Intervention: Existing health services (control group).
Number of subjects: 6361

Group type: EXPERIMENTAL
Intervention: Community-based screening and treatment for Chlamydia trachomatis and Neisseria gonorrhoeae.
Number of subjects: 6361

Group type: EXPERIMENTAL
Intervention: Community-based screening and treatment for Trichomonas vaginalis.
Number of subjects: 6361

Group type: EXPERIMENTAL
Intervention: Community-based screening and treatment for Neisseria gonorrhoeae.
Number of subjects: 6361
Study: 39551062

Group type: EXPERIMENTAL
Intervention: MDA with dihydroartemisinin-piperaquine and ivermectin (300 μg/kg per day)
Number of subjects: 25882

Group type: COMPARATOR
Intervention: MDA with dihydroartemisinin-piperaquine and placebo
Number of subjects: 25882
Study: 39551064

Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg starting 2 weeks before radiotherapy then every 4 weeks starting week 2 of radiotherapy (seven cycles)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Cetuximab 400 mg/m2
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 190

Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 190
Study: 39551093

Group type: EXPERIMENTAL
Intervention: Higher sCD14 concentrations
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Higher I-FABP concentrations
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Higher alpha-1-acid glycoprotein concentrations
Number of subjects: 240
Study: 39551132

Group type: EXPERIMENTAL
Intervention: Apixaban, 2.5 mg twice daily for three months
Number of subjects: 186

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 186
Study: 39551147

Group type: EXPERIMENTAL
Intervention: Enhanced HIV prevention intervention with accommodation strategies
Number of subjects: 50

Group type: COMPARATOR
Intervention: HIV prevention intervention as treatment per usual (active control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Weekly PrEP adherence assessments
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Acceptability ratings of intervention content and accommodation strategies
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Feasibility measures via participant recruitment and retention
Number of subjects: 50
Study: 39551167

Group type: EXPERIMENTAL
Intervention: mAFP (Impella CP) plus standard care
Number of subjects: 355

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 355
Study: 39551349

Group type: EXPERIMENTAL
Intervention: Measured energy expenditure
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nutritional intervention timing and strategies
Number of subjects: 50
Study: 39551356

Group type: EXPERIMENTAL
Intervention: Complementary dietary fibers (total dietary fiber - complementary foods (g))
Number of subjects: 68

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 68
Study: 39551469

Group type: EXPERIMENTAL
Intervention: Deulorlatinib 60 mg once per day (recommended phase 2 dose)
Number of subjects: 198
Study: 39551470

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consolidation immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 39551581

Group type: EXPERIMENTAL
Intervention: Serum neutrophil gelatinase-associated lipocalin (NGAL) measured on ED admission
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: NGAL for predicting AKI on day 2
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Adjusted NGAL for predicting AKI on day 2
Number of subjects: 197
Study: 39551579

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards model for survival time from index assessment in the derivation cohort (N≈140,000).
Number of subjects: 200000

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards model for survival time from index assessment in the validation cohort (N≈60,000).
Number of subjects: 200000
Study: 39551590

Group type: EXPERIMENTAL
Intervention: adalimumab-adbm (Cyltezo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: adalimumab RP (Humira)
Number of subjects: 0
Study: 39551600

Group type: EXPERIMENTAL
Intervention: MEDI5395 (recombinant attenuated Newcastle disease virus) administered intravenously as six doses over 15-18 days
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Durvalumab (anti-PD-L1 immune checkpoint inhibitor)
Number of subjects: 39